Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.78 |
| ▸ | USP2 | O75604 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13947063 | 0.85 | ALDH1A1 (0.82) | ALDH1A1L3MBTL1USP2NPSR1CYP1A2 | |
| SCHEMBL12426371 | 0.84 | ALDH1A1 (0.80) | ALDH1A1L3MBTL1USP2NPSR1CYP1A2 | |
| SCHEMBL2919972 | 0.84 | SMN1; SMN2 (0.82) | ALDH1A1L3MBTL1CYP2C19HPGDKDM4E | |
| Picotamide SCHEMBL30206880 | 0.83 | CYP1A2 (1.00) | ALDH1A1L3MBTL1USP2NPSR1CYP1A2 | |
| Picotamide SCHEMBL30254057 | 0.83 | CYP1A2 (1.00) | ALDH1A1L3MBTL1USP2NPSR1CYP1A2 | |
| Picotamide SCHEMBL137025 | 0.83 | CYP1A2 (1.00) | ALDH1A1L3MBTL1USP2NPSR1CYP1A2 | |
| SCHEMBL11629761 | 0.82 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1USP2NPSR1CYP2C19 | |
| SCHEMBL14082524 | 0.82 | L3MBTL1 (0.60) | ALDH1A1L3MBTL1USP2NPSR1CYP1A2 | |
| SCHEMBL21246573 | 0.82 | ALDH1A1 (0.80) | ALDH1A1L3MBTL1USP2NPSR1CYP1A2 | |
| Picotamide SCHEMBL4877561 | 0.82 | CYP1A2 (0.98) | ALDH1A1L3MBTL1USP2NPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635839-B1 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2010-09-01 | — | — | EP | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | ALDH1A1 229/4885L3MBTL1 3522/4885USP2 1772/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | ALDH1A1 229/4885L3MBTL1 3522/4885USP2 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.